TP53 and B-cell chronic lymphocytic leukemia: These include i) the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status, which divides patients into a poor-prognostic group with unmutated IGHV genes (U-CLL) or a favorable-prognostic group with mutated IGHV genes (M-CLL) (4, 5), and ii) the presence (or absence) of certain genomic lesions, such as deletions of 13q (35-45%), 11q (10-20%), and 17p (5-7%), and trisomy 12 (10-15%), as well as TP53 mutations (1, 6, 7).